During the last years, the improvement in the molecular characteristics of prostate cancer has increased the relevance for a biomarker-driven therapeutic approach and, in this sense, the role of continuing AR signaling during the oncological progression as a key pathway [1]. Here, AR is linked to prostate carcinoma.